Clinical Trial Update: Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating a proteasome inhibitor in combination with CPX-351 for newly diagnosed TP53-mutated acute myeloid leukemia is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)
• Proteasome inhibitor

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myeloid Leukemia, TP53 | Phase 1, Phase 2 | Status: RECRUITING